Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, shared on LinkedIn:
“I was honored to attend the Amgen Advocacy Summit this week, and participate in a taped interview at their California headquarters.
The Amgen Advocacy Summit brought together advocacy leaders and Amgen leadership to connect, share insights, and collaborate to provide meaningful impact to patients. The summit featured discussions, interactive sessions, and networking opportunities designed to strengthen partnerships that drive progress.
I took this opportunity to share the cutting-edge work the Colorectal Cancer Alliance is spearheading through our Project Cure CRC initiative, and more specifically, our KLEOS adaptive clinical trial platform. KLEOS is the first-ever colorectal cancer platform that will match patients with new treatments, faster, based on their biomarkers.
We are grateful to partners like Amgen who help advance cutting-edge science and support advocacy efforts. Together, by sharing insights and collaborating on innovation, we are working toward a future free of colorectal cancer.
To learn more or get involved with Project Cure CRC visit.”
Other articles featuring Michael Sapienza on OncoDaily.